Patents by Inventor Lydie DIEUDONNE

Lydie DIEUDONNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS
    Publication number: 20240131138
    Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 25, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
  • CHLAMYDIA TRACHOMATIS ANTIGENIC POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES
    Publication number: 20240124532
    Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 18, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research Institute
    Inventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD